其它产品项目整合

项目整合的本质是一项集合成方法学、反应工程学与过程分析技术于一体的系统工程。其核心逻辑可以概括为以下几点：源头优选：利用如N-硝胺化学等底层方法学突破，从分子层面颠覆传统高成本、高污染路线。过程强化：依托连续流技术，攻克有机金属试剂应用、光化学反应放大等“不可能”任务，实现高危工艺的本质安全。系统集成：整合“反应-淬灭-分离”全流程，利用微流控与在线分析技术，消除批次间的差异，实现药品制造的连续化与智能化。当前，中间体工艺研发正在经历从“经验驱动”向“数据驱动”的转变。AI辅助路线设计、自动化高通量筛选与连续制造平台的结合，将使得“分子结构与最优工艺路径”之间的映射关系逐渐清晰。未来的竞争优势，将属于那些能够将底层化学创新与先进工程技术进行无缝整合的研发体系。
备注: 根据相关法律法规, 本站点不显示有法律约束管制的产品, 如有遗漏, 请自行鉴别,或提交我们及时更新撤除.
如有产品相关项目调研推广服务, 请致函联系我们

客户展示

其它产品项目整合

Tesmilifene CAS Registry Number: 98774-23-3 替米利芬

CAS Name: N,N-Diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine
Additional Names: DPPE
Percent Composition: C 80.52%, H 8.89%, N 4.94%, O 5.65%
Literature References: Intracellular histamine antagonist with chemopotentiating and cytoprotective activity. Structurally similar to tamoxifen, q.v., although binds anti-estrogen binding site (AEBS) with no affinity for the estrogen receptor. Prepn: L. J. Brandes, M. W. Hermonat, Biochem. Biophys. Res. Commun. 123, 724 (1984); and use as antineoplastic: eidem, US 4803227 (1989 to Univ. Manitoba); and study of binding affinity: M. Poirot et al., Bioorg. Med. Chem. 8, 2007 (2000). Spectral analysis of interaction with P450 isozymes: L. J. Brandes et al., Cancer Chemother. Pharmacol. 45, 298 (2000). Clinical evaluation in combination with cyclophosphamide in prostate cancer: L. J. Brandes et al., J. Clin. Oncol. 13, 1398 (1995); in combination with doxorubicin in breast cancer: L. Reyno et al., J. Clin. Oncol. 22, 269 (2004).

Gadobenate Dimeglumine CAS Registry Number: 127000-20-8 钆贝葡胺

CAS Name: 1-Deoxy-1-(methylamino)-D-glucitol [4-(carboxy-kO)-5,8,11-tris[(carboxy-kO)methyl]-1-phenyl-2-oxa-5,8,11-triazatridecan-13-oato(5-)-kN5,kN8,kN11,kO13]gadolinate(2-) (2:1)
Additional N...
Literature References: Intravascular paramagnetic MRI contrast agent. Prepn: E. Felder et al., EP 230893; eidem, US 4916246 (1987, 1990 both to Bracco); F. Ungerri et al., Inorg. Chem. 34, 633 (1995). HPLC determn in biological samples: T. Arbughi et al., J. Chromatogr. B 713, 415 (1998). Physicochemical properties: C. de Haen et al., J. Comput. Assist. Tomogr. 23, Suppl. 1, S161 (1999). Pharmacology: P. Tirone et al., ibid. S195. Pharmacokinetics: V. Lorusso et al., ibid. S181. Toxicology: A. Morisetti et al., ibid. S207. Clinical study in MRI of liver lesions: J. Petersein et al. Radiology 215, 727 (2000). Review of clinical studies: B. Hamm et al., J. Comput. Assist. Tomogr. 23, Suppl. 1, S53-S60 (1999).

N-Iodosaccharin CAS Registry Number: 86340-94-5 N-碘代糖精

CAS Name: 2-Iodo-1,2-benzisothiazol-3(2H)-one 1,1-dioxide
Additional Names: NISac
Percent Composition: C 27.20%, H 1.30%, I 41.06%, N 4.53%, O 15.53%, S 10.37%
Literature References: Iodination reagent. Prepn: M. Papadopoulou, A. Varvoglis, J. Chem. Res. Synop. 1983, 66. Synthesis and use for iodination of aromatics and alkenes: D. Dolenc, Synlett 2000, 544. As an activator of thioglycosides: M. Aloui, A. J. Fairbanks, ibid. 2001, 797; eidem, Chem. Commun. 2001, 1406. Iodination of enol acetates and diones: D. Dolenc, Synth. Commun. 33, 2917 (2003); of isatins: S. P. L. de Souza et al., Heterocycl. Commun. 9, 31 (2003).

Bentoquatam CAS Registry Number: 1340-69-8

CAS Name: Quaternium 18-bentonite
Additional Names: bis(hydrogenated tallow alkyl)dimethylammonium complex with sodium bentonite
Trademarks: Bentone 34 (Rheox); Ivy Block (Enviroderm); Tixog...
Literature References: Ion exchange addition product of the montmorillonite clay, bentonite, q.v., and quaternium-18, a dimethyl, ditallow quaternary ammonium salt containing predominantly C18 alkyl chains. Acts as a barrier to block urushiol, q.v., from the skin. Prepn of aliphatic ammonium bentonites: E. A. Hauser, US 2531427 (1950); and organophilic properties: J. W. Jordan, J. Phys. Colloid Chem. 53, 294 (1949); idem et al., ibid. 54, 1196 (1950). Use as stationary phase in GSC and HPLC: D. W. Grant et al., J. Chromatogr. 99, 721 (1974). Description of properties, toxicology and use in cosmetics: J. Am. Coll. Toxicol. 1, 71-83 (1982). Clinical trial in poison ivy/oak dermatitis: J. G. Marks, Jr. et al., J. Am. Acad. Dermatol. 33, 212 (1995).

Lasalocid A CAS Registry Number: 25999-31-9 拉沙洛西

CAS Name: 6-[(3R,4S,5S,7R)-7-[(2S,3S,5S)-5-Ethyl-5-[(2R,5R,6S)-5-ethyltetrahydro-5-hydroxy-6-methyl-2H-pyran-2-yl]tetrahydro-3-methyl-2-furanyl]-4-hydroxy-3,5-dimethyl-6-oxononyl]-2-hydroxy-3-meth...
Literature References: Ionophorous (transport-inducing) antibiotic isolated from an unidentified Streptomyces from soil samples of Hyde Park, Mass.: Berger et al., J. Am. Chem. Soc. 73, 5295 (1951). Prepn and activity of title compd and derivs: A. Stempel, J. Westley, DE 2040998; eidem, US 3715372 (1971, 1973 to Hoffmann-La Roche); Westley et al., J. Med. Chem. 16, 397 (1973). Structure: eidem, Chem. Commun. 1970, 71. Crystal and molecular structure studies: Johnson et al., ibid. 72; J. Am. Chem. Soc. 92, 4428 (1970). Total synthesis: T. Nakata et al., ibid. 100, 2933 (1978); R. E. Ireland et al., ibid. 102, 1155 (1980). Complete assignment of 13C-NMR spectra of lasalocid A and its sodium salt: H. Seto et al., J. Antibiot. 31, 289 (1978). Effect in coccidiosis: G. M. J. Horton, P. H. G. Stockdale, Am. J. Vet. Res. 42, 433 (1981). Biosynthesis: Westley et al., Chem. Commun. 1970, 1467; C. R. Hutchinson et al., J. Am. Chem. Soc. 103, 5953, 5956 (1981). Mode of action studies: Lin, Kun, Biochem. Biophys. Res. Commun. 50, 820 (1973). Isoln and structure of four homologs, lasalocids B, C, D, E from Streptomyces lasaliensis: J. W. Westley et al., J. Antibiot. 27, 744 (1974).

Iridomyrmecin CAS Registry Number: 485-43-8 (4aa,7aa)-八氢-4b,7a-二甲基环戊并[c]吡喃-3-酮

CAS Name: [4S-(4a,4ab,7b,7ab)]-Hexahydro-4,7-dimethylcyclopenta[c]pyran-3(1H)-one
Additional Names: 2-(hydroxymethyl)-a,3-dimethylcyclopentaneacetic acid d-lactone; iridomyrmexin
Percent Com...
Literature References: Iridolactone isolated from the Argentine ant Iridomyrmex humilis Mayr., Dolichoderinae. Exhibits antibacterial and insect antifeedant activity. Isoln: Pavan, Ric. Sci. 19, 1011 (1949); Chim. Ind. (Milan) 37, 625 (1955); Fusco et al., ibid. 251, 958; Cavill et al., Aust. J. Chem. 9, 288 (1956); 10, 352 (1957). Synthesis: Korte et al., Tetrahedron 6, 201 (1959); Sisido et al., J. Org. Chem. 29, 3361 (1964); R. S. Matthews, J. K. Whitesell, ibid. 40, 3312 (1975); Y. Yamada et al., Chem. Lett. 1978, 1405; P. Callant et al., Tetrahedron 37, 2085 (1981). Stereochemistry: Korte et al., Ber. 94, 1952 (1961); McConnell et al., Tetrahedron Lett. 1962, 445; Büchi, Manning, Tetrahedron 18, 1049 (1962). Activity as bactericide and insecticide: M. Pavan, Z. Hyg. Infektionskrankh. 134, 136 (1952), C.A. 46, 9796f (1952).

Coprogen CAS Registry Number: 31418-71-0

Percent Composition: C 51.16%, H 6.50%, Fe 6.80%, N 10.23%, O 25.31%
Literature References: Iron-contg, growth-promoting complex. Isoln from Penicillium spp: Hesseltine et al., J. Am. Chem. Soc. 74, 1362 (1952). Pidacks et al., ibid. 75, 6064 (1953); Gaeumann, Vischer, US 3297526 (1967 to Ciba). Isoln from Aspergillaceae: Zaehner et al., Arch. Mikrobiol. 45, 119 (1963). Structure: Keller-Schierlein, Diekmann, Helv. Chim. Acta 53, 2035 (1970).

Lumichrome CAS Registry Number: 1086-80-2 7,8-二甲基咯嗪

CAS Name: 7,8-Dimethylbenzo[g]pteridine-2,4-(1H,3H)-dione
Additional Names: 7,8-dimethylalloxazine; 6,7-dimethylalloxazine
Percent Composition: C 59.50%, H 4.16%, N 23.13%, O 13.21%
Literature References: Irradiation product of riboflavine. Isoln: Karrer et al., Helv. Chim. Acta 17, 1010 (1934). Prepn: Tishler, Wellman, US 2417143 (1947 to Merck Co.); Cresswell, Wood, J. Chem. Soc. 1960, 4768; Bardos et al., US 3057865 (1962 to Armour Pharm. Co.); Seng, Ley, Angew. Chem. 84, 1061 (1972).

Exemestane CAS Registry Number: 107868-30-4 依西美坦

CAS Name: 6-Methyleneandrosta-1,4-diene-3,17-dioneTrademarks: Aromasin (Pharmacia Upjohn)
Percent Composition: C 81.04%, H 8.16%, O 10.80%
Literature References: Irreversible aromatase inhibitor. Prepn: E. Di Salle et al., DE 3622841; F. Buzzetti et al., US 4808616 (1987, 1989 both to Farmitalia Carlo Erba). Pharmacology: D. Giudici et al., J. Steroid Biochem. 30, 391 (1988). HPLC determn in plasma: M. Breda et al., J. Chromatogr. 620, 225 (1993). Clinical pharmacology: T. R. J. Evans et al., Cancer Res. 52, 5933 (1992). Review of clinical experience in primary and secondary therapy for breast cancer: J. M. Dixon, Expert Rev. Anticancer Ther. 2, 267-275 (2002). Clinical trial in sequential therapy following tamoxifen in breast cancer: R. C. Coombes et al., N. Engl. J. Med. 350, 1081 (2004).

Eniluracil CAS Registry Number: 59989-18-3 5-乙炔基尿嘧啶

CAS Name: 5-Ethynyl-2,4(1H,3H)-pyrimidinedione
Additional Names: 5-ethynyluracil; 5-EUPercent Composition: C 52.95%, H 2.96%, N 20.58%, O 23.51%
Literature References: Irreversible inhibitor of dihydropyrimidine dehydrogenase, the rate-determining enzyme in catabolism of 5-fluorouracil, q.v. Prepn: J. Perman et al., Tetrahedron Lett. 1976, 2427; P. J. Barr et al., Nucleic Acids Res. 3, 2845 (1976). Large scale synthesis: N. G. Kundu, S. A. Schmitz, J. Heterocycl. Chem. 19, 463 (1982). Crystal structure determn: M. Sacchetti et al., J. Pharm. Sci. 90, 1049 (2001). Mechanism-based inactivation of dihydropyrimidine dehydrogenase: D. J. T. Porter et al., J. Biol. Chem. 267, 5236 (1992). Prolongs plasma concentration of 5-fluorouracil: D. P. Baccanari et al., Proc. Natl. Acad. Sci. USA 90, 11064 (1993). Clinical safety and efficacy: R. A. Humerickhouse et al., Clin. Cancer Res. 5, 291 (1999). Clinical study with 5-fluorouracil in advanced pancreatic cancer: M. L. Rothenberg et al., Ann. Oncol. 13, 1576 (2002); in metastatic/advanced colorectal cancer: R. L. Schilsky et al., J. Clin. Oncol. 20, 1519 (2002). Review of clinical development: J. A. Hohneker, Oncology 12, 52-56 (1998).